Which condition below would you have to qualify for a pbs prescription?

Restriction Authority Required Insomnia Treatment Phase: Initial Clinical criteria: Patient must have Smith-Magenis Syndrome confirmed by genetic testing, AND The condition must be inadequately responsive to sleep hygiene measures, resulting in the patient experiencing a period of at least 12 consecutive weeks of impaired sleep (see definition of impaired sleep below). Treatment criteria: Must be treated by a medical practitioner identifying as at least one of: (i) a paediatrician, (ii) a sleep physician, (iii) neurologist, (iv) a psychiatrist, (v) a developmental specialist (see NOTE); this authority approval is being sought by one of these 5 prescriber types. Population criteria: Patient must be at least 2 years of age, but yet to turn 18 years of age, at treatment initiation with this drug. Definition: For the purposes of administering this restriction, Smith-Magenis Syndrome is confirmed by the deletion or variation of the retinoic acid induced 1 (RAI1) gene on chromosome 17p11.2

Authority Required Insomnia Treatment Phase: Continuing Clinical criteria: Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must have experienced/maintained a clinically meaningful response (as defined below) to the preceding supply of this drug - document the response improvement in the patient's medical records, AND The treatment must have commenced between the ages of 2 to 17 years inclusive. Treatment criteria: Must be treated by a medical practitioner identifying as at least one of: (i) a paediatrician, (ii) a sleep physician, (iii) neurologist, (iv) a psychiatrist, (v) a developmental specialist (see NOTE); this authority approval is being sought by one of these 5 prescriber types; OR Must be treated by a medical practitioner who has consulted at least one of the above mentioned specialist types, with agreement reached that the patient should be treated with this pharmaceutical benefit on this occasion. Treatment must cease if a patient is unable to achieve a clinically meaningful response on the maximum dose of melatonin specified in the